September 11, 2009 1:54 AM
- Text
Former CellCyte Execs Sued by SEC for Role in Pump and Dump Stock Scheme
(MoneyWatch)
In case you were wondering why counsel always cuts the hype out of your press releases--CellCyte Genetics and its former top execs got slapped with an SEC lawsuit for their role in a hype-driven pump-and-dump stock scheme.
Stem cell player CellCyte ran into trouble when it teamed up with investor G. Brent Pierce, who had already been barred from trading in Canada because of his role in pumping and dumping stocks like Lexington Resources and Morgan Creek Energy. You'd think that might have raised a red flag with CellCyte, but CEO Gary Reys told the Seattle Times that his lawyers had investigated Pierce and found nothing wrong.
Pierce blasted out hypey newsletters and brochures claiming CellCyte's technology "truly could be the most astonishing and important medical breakthrough in your lifetime!" and that the stock "could be the chance of your lifetime to turn $10,000 into $4 million, maybe even $15 million!" CellCyte's shares rocketed from $4 to $7.50 ?€" but Reys told the Times the activity was simply an "amazing" show of investor confidence.
CellCyte's stock is now trading at four cents. It had $923 in cash as of June 30 and is basically in limbo, trying to fundraise and figure out if the technology it licensed from the government is worth a crap or not.
And this week the SEC sued CellCyte, Reys and former CSO Ronald Berninger for "for falsely telling investors that the company's cutting-edge stem cell technology had been proven successful" and was cleared for clinical trials.
According to the SEC press release:
CellCyte and Berninger agreed to a settlement, accepting a permanent injunction without admitting or denying guilt. Berninger also agreed to pay a $50,000 penalty and be barred from serving as an officer or director of a public company for five years.
Reys case is still pending.
Jail photo by Flickr user D.C.Atty, CC
In case you were wondering why counsel always cuts the hype out of your press releases--CellCyte Genetics and its former top execs got slapped with an SEC lawsuit for their role in a hype-driven pump-and-dump stock scheme.Stem cell player CellCyte ran into trouble when it teamed up with investor G. Brent Pierce, who had already been barred from trading in Canada because of his role in pumping and dumping stocks like Lexington Resources and Morgan Creek Energy. You'd think that might have raised a red flag with CellCyte, but CEO Gary Reys told the Seattle Times that his lawyers had investigated Pierce and found nothing wrong.
Pierce blasted out hypey newsletters and brochures claiming CellCyte's technology "truly could be the most astonishing and important medical breakthrough in your lifetime!" and that the stock "could be the chance of your lifetime to turn $10,000 into $4 million, maybe even $15 million!" CellCyte's shares rocketed from $4 to $7.50 ?€" but Reys told the Times the activity was simply an "amazing" show of investor confidence.
CellCyte's stock is now trading at four cents. It had $923 in cash as of June 30 and is basically in limbo, trying to fundraise and figure out if the technology it licensed from the government is worth a crap or not.
And this week the SEC sued CellCyte, Reys and former CSO Ronald Berninger for "for falsely telling investors that the company's cutting-edge stem cell technology had been proven successful" and was cleared for clinical trials.
According to the SEC press release:
CellCyte did not know how to properly formulate the stem cell compound, had never attempted experiments with the compound to repair organs, and had not satisfied any of the FDA requirements to begin human clinical trials.And while the company claimed it had no control over Pierce, the SEC said Berninger approved the misleading statements and Reys approved fraudulent SEC filings.
CellCyte and Berninger agreed to a settlement, accepting a permanent injunction without admitting or denying guilt. Berninger also agreed to pay a $50,000 penalty and be barred from serving as an officer or director of a public company for five years.
Reys case is still pending.
Jail photo by Flickr user D.C.Atty, CC
Latest Now in MoneyWatch
- EU: Greece must cut deeper to get bailout
- Big banks, gov't officials strike $25B deal
- LinkedIn swings back to profit
- LinkedIn doubles revenue, beats growth estimates
- Kodak to stop making digital cameras, frames
- Market cap, schmarket cap, Apple still gets no respect
- Philip Morris Int'l income up nearly 8 percent
- Survey: Small biz plans big hires in 2012
- Freddie Mac: Mortgages inch higher but stay low
- Will the European debt crisis sink Obama's re-election?
- Banks in $25B deal to settle foreclosure abuses
- Joe Coffee: Scaling up without selling your soul
- Greek agreement accomplishes nothing
- 401K plans: New rules make costs clearer
- Are women leaders selling themselves short?
- Ask the Experts: New 401(k) rules
- Mortgage lenders strike a deal
Latest CBS News Headlines
on Facebook
on CBS News
- NYSE Euronext profit down on blocked merger costs
- Why Bank of America is the new Citigroup
- Barclays bank profit down 15 pct in 2011
- France's Total gets oil price profit boost
on Facebook
- Tenn. father charged with murdering couple who"unfriended" daughter on Facebook
- Adele opens up about vocal cord surgery
- Mo. teen gets life in prison for murder of 9-year-old girl
on CBS News






